vs

Side-by-side financial comparison of Cambium Networks Corp (CMBM) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $40.3M, roughly 1.9× Cambium Networks Corp). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -23.2%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $-10.8M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -27.2%).

Cambium Networks Corporation is an American manufacturer of wireless telecommunications equipment, including Enterprise WiFi, Network switch, Internet of Things, and fixed wireless broadband and Wi-Fi for enterprises products for Internet access. Publicly traded on the NASDAQ stock exchange, it spun out of Motorola in October 2011.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

CMBM vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.9× larger
PBYI
$75.5M
$40.3M
CMBM
Growing faster (revenue YoY)
PBYI
PBYI
+50.9% gap
PBYI
27.7%
-23.2%
CMBM
More free cash flow
PBYI
PBYI
$25.2M more FCF
PBYI
$14.4M
$-10.8M
CMBM
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
-27.2%
CMBM

Income Statement — Q4 FY2024 vs Q4 FY2025

Metric
CMBM
CMBM
PBYI
PBYI
Revenue
$40.3M
$75.5M
Net Profit
$-7.2M
Gross Margin
36.6%
69.3%
Operating Margin
-28.4%
22.7%
Net Margin
-17.9%
Revenue YoY
-23.2%
27.7%
Net Profit YoY
71.0%
EPS (diluted)
$-0.26
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMBM
CMBM
PBYI
PBYI
Q4 25
$75.5M
Q3 25
$54.5M
Q2 25
$52.4M
Q1 25
$46.0M
Q4 24
$40.3M
$59.1M
Q3 24
$44.7M
$80.5M
Q2 24
$45.2M
$47.1M
Q1 24
$47.1M
$43.8M
Net Profit
CMBM
CMBM
PBYI
PBYI
Q4 25
Q3 25
$8.8M
Q2 25
$5.9M
Q1 25
$3.0M
Q4 24
$-7.2M
Q3 24
$-34.5M
$20.3M
Q2 24
$-14.2M
$-4.5M
Q1 24
$-18.4M
$-4.8M
Gross Margin
CMBM
CMBM
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
36.6%
76.4%
Q3 24
43.6%
63.9%
Q2 24
32.5%
77.4%
Q1 24
29.8%
75.5%
Operating Margin
CMBM
CMBM
PBYI
PBYI
Q4 25
22.7%
Q3 25
17.6%
Q2 25
12.7%
Q1 25
8.7%
Q4 24
-28.4%
22.6%
Q3 24
-69.6%
27.4%
Q2 24
-27.2%
-4.6%
Q1 24
-33.1%
-5.3%
Net Margin
CMBM
CMBM
PBYI
PBYI
Q4 25
Q3 25
16.2%
Q2 25
11.2%
Q1 25
6.5%
Q4 24
-17.9%
Q3 24
-77.3%
25.2%
Q2 24
-31.5%
-9.6%
Q1 24
-39.2%
-11.0%
EPS (diluted)
CMBM
CMBM
PBYI
PBYI
Q4 25
$0.26
Q3 25
$0.17
Q2 25
$0.12
Q1 25
$0.06
Q4 24
$-0.26
$0.40
Q3 24
$-1.22
$0.41
Q2 24
$-0.51
$-0.09
Q1 24
$-0.66
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMBM
CMBM
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$97.5M
Total DebtLower is stronger
$67.6M
$22.7M
Stockholders' EquityBook value
$-3.2M
$130.3M
Total Assets
$173.7M
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMBM
CMBM
PBYI
PBYI
Q4 25
$97.5M
Q3 25
$94.4M
Q2 25
$96.0M
Q1 25
$93.2M
Q4 24
$101.0M
Q3 24
$96.7M
Q2 24
$96.8M
Q1 24
$107.2M
Total Debt
CMBM
CMBM
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$67.6M
$68.0M
Q3 24
$67.6M
$79.3M
Q2 24
$68.9M
$90.7M
Q1 24
$63.8M
$102.0M
Stockholders' Equity
CMBM
CMBM
PBYI
PBYI
Q4 25
$130.3M
Q3 25
$115.3M
Q2 25
$104.7M
Q1 25
$97.1M
Q4 24
$-3.2M
$92.1M
Q3 24
$1.9M
$71.1M
Q2 24
$34.1M
$48.5M
Q1 24
$45.0M
$51.0M
Total Assets
CMBM
CMBM
PBYI
PBYI
Q4 25
$216.3M
Q3 25
$202.9M
Q2 25
$194.9M
Q1 25
$196.2M
Q4 24
$173.7M
$213.3M
Q3 24
$194.3M
$220.7M
Q2 24
$221.1M
$205.0M
Q1 24
$219.8M
$214.1M
Debt / Equity
CMBM
CMBM
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
36.12×
1.12×
Q2 24
2.02×
1.87×
Q1 24
1.42×
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMBM
CMBM
PBYI
PBYI
Operating Cash FlowLast quarter
$-10.4M
$14.4M
Free Cash FlowOCF − Capex
$-10.8M
$14.4M
FCF MarginFCF / Revenue
-26.8%
19.1%
Capex IntensityCapex / Revenue
1.1%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-21.4M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMBM
CMBM
PBYI
PBYI
Q4 25
$14.4M
Q3 25
$9.7M
Q2 25
$14.1M
Q1 25
$3.6M
Q4 24
$-10.4M
$15.6M
Q3 24
$8.9M
$11.0M
Q2 24
$2.4M
$1.0M
Q1 24
$-15.9M
$11.2M
Free Cash Flow
CMBM
CMBM
PBYI
PBYI
Q4 25
$14.4M
Q3 25
$9.7M
Q2 25
$14.1M
Q1 25
$3.6M
Q4 24
$-10.8M
$15.6M
Q3 24
$6.8M
$11.0M
Q2 24
$87.0K
$1.0M
Q1 24
$-17.4M
FCF Margin
CMBM
CMBM
PBYI
PBYI
Q4 25
19.1%
Q3 25
17.7%
Q2 25
26.8%
Q1 25
7.7%
Q4 24
-26.8%
26.4%
Q3 24
15.2%
13.7%
Q2 24
0.2%
2.1%
Q1 24
-37.0%
Capex Intensity
CMBM
CMBM
PBYI
PBYI
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
1.1%
0.0%
Q3 24
4.8%
0.0%
Q2 24
5.1%
0.0%
Q1 24
3.3%
0.0%
Cash Conversion
CMBM
CMBM
PBYI
PBYI
Q4 25
Q3 25
1.10×
Q2 25
2.41×
Q1 25
1.21×
Q4 24
Q3 24
0.54×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CMBM
CMBM

Enterprise$16.6M41%
Point To Multi Point$16.4M41%
Other$5.8M14%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons